Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lowered its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 3.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,586,803 shares of the biopharmaceutical company's stock after selling 80,468 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.87% of Amicus Therapeutics worth $24,368,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Amicus Therapeutics during the third quarter valued at about $55,000. R Squared Ltd bought a new stake in Amicus Therapeutics during the fourth quarter valued at about $79,000. KBC Group NV boosted its position in Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after purchasing an additional 3,120 shares in the last quarter. Stephens Inc. AR bought a new stake in Amicus Therapeutics during the fourth quarter valued at about $101,000. Finally, Choreo LLC bought a new stake in Amicus Therapeutics during the fourth quarter valued at about $103,000.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on FOLD shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Morgan Stanley reiterated an "equal weight" rating and issued a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Finally, Wells Fargo & Company decreased their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.75.

Remove Ads

Amicus Therapeutics Stock Performance

Shares of NASDAQ:FOLD traded down $0.07 during trading on Friday, hitting $9.01. The stock had a trading volume of 2,928,681 shares, compared to its average volume of 2,390,593. Amicus Therapeutics, Inc. has a 12-month low of $8.55 and a 12-month high of $12.65. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of -50.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The stock has a 50-day simple moving average of $9.35 and a two-hundred day simple moving average of $10.08.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.